INVO Fertility Restates Financials After Non-Reliance on Prior Statements

INVO Fertility Inc. (NASDAQ: IVF) disclosed on June 2, 2026 that its management and audit committee concluded the company should no longer rely on certain previously issued financial statements, according to an SEC Form 8-K filed that day.

The filing, submitted under Item 4.02, identifies the specific periods subject to restatement though it does not publicly detail the underlying error, fraud or accounting policy change or quantify the magnitude in the initial disclosure. Item 9.01 of the same form states that the company will file amended periodic reports containing the restated financial statements and related disclosures as soon as practicable.

The action affects all current and prospective investors in IVF as well as any counterparties relying on the company’s prior SEC filings for the restated periods. Public companies must maintain accurate and reliable financial reporting under SEC rules; once non-reliance is declared, the original statements lose legal standing for purposes such as securities offerings, debt covenants and regulatory compliance.

Operationally the company shifts from reliance on the prior statements to a corrected set. The restated filings must be completed and submitted to the SEC, after which the company regains compliance with its Exchange Act reporting obligations for the affected quarters or years.

No specific deadline for the amendments is stated in the 8-K, but standard SEC practice requires prompt filing once the restatement is prepared.

Downstream, the company must now finalize and furnish the restated financial statements, which will supersede the prior versions in all future SEC submissions and investor communications. This process can delay other planned filings, affect compliance with listing standards on Nasdaq, and require updated disclosures in any ongoing registration statements or proxy materials.

Lenders or contractual counterparties that reference the company’s SEC reports may also need to review the corrected numbers against existing agreements.

This is the first such non-reliance disclosure by INVO Fertility Inc. in the current reporting cycle. The company, which operates in the assisted reproductive technology sector, had previously filed periodic reports that are now subject to correction before they can be relied upon by investors or regulators.

Primary sources: SEC Form 8-K filed June 2, 2026 (Accession No. 0001493152-26-026772).